The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions
Open accessAbstract
Gastric inhibitory polypeptide (GIP) exhibits potent insulinotropic effects on β-cells and anabolic effects on bone formation and fat accumulation. We explored the impact of reduced GIP levels in vivo on glucose homeostasis, bone formation, and fat accumulation in a novel GIP-GFP knock-in (KI) mouse. We generated GIP-GFP KI mice with a truncated prepro-GIP gene. The phenotype was assessed in heterozygous and homozygous states in mice on a control fat diet and a high-fat diet (HFD) in vivo and in vitro. Heterozygous GIP-GFP KI mice (GIP-reduced mice [GIPgfp/+]) exhibited reduced GIP secretion; in the homozygous state (GIP-lacking mice [GIPgfp/gfp]), GIP secretion was undetectable. When fed standard chow, GIPgfp/+ and GIPgfp/gfp mice showed mild glucose intolerance with decreased insulin levels; bone volume was decreased in GIPgfp/gfp mice and preserved in GIPgfp/+ mice. Under an HFD, glucose levels during an oral glucose tolerance test were similar in wild-type, GIPgfp/+, and GIPgfp/gfp mice, while insulin secretion remained lower. GIPgfp/+ and GIPgfp/gfp mice showed reduced obesity and reduced insulin resistance, accompanied by higher fat oxidation and energy expenditure. GIP-reduced mice demonstrate that partial reduction of GIP does not extensively alter glucose tolerance, but it alleviates obesity and lessens the degree of insulin resistance under HFD conditions, suggesting a potential therapeutic value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“Following secretion, the hormone exerts its effects through specific, G-protein–coupled receptors located mainly in the stomach, pancreas, central nervous system, bone, and adipose tissue (2,3).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 4×
“There are reports showing that increased energy expenditure is coupled with increased locomotor activity; disruption of GIPR signaling increases the activity of mice not only under HFD conditions, as in mice treated with GIPR antagonist (14) and GIPRKO mice (12), but also leads to increased spontaneous activity even d…”
BackgroundInfluentialSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production
Mehran, A. E., Templeman, N. M., Brigidi, G. S., Lim, G. E., Chu, K.-Y., Hu, X., Botezelli, J. D., Asadi, A., Hoffman, B. G., Kieffer, T. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.019 · Cited by 498
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 11×
“GIPgfp/gfp mice exhibit a phenotype similar to that of GIPRKO mice regarding glucose tolerance, bone formation, and adipose tissue expansion (Table 1).”
BackgroundInfluentialParker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324 · cited 1×
“However, there are reports confirming the existence of double incretin-positive cells (K/L cells) in the intestine (20), and the existence of populations of K cells that coexpress not only GIP but also glucagon, somatostatin, secretin, and, to a smaller extent, some other hormones (21,22).”
BackgroundExtrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198 · cited 10×
“GIP operates as an anabolic hormone in the bone, where it stimulates incorporation of meal-derived Ca into bone and bone building (13), and reduces bone absorption by inhibiting osteoclastic activity.”
BackgroundSelf-citationAlthage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180 · cited 3×
“Although WT mice showed overt obesity, GIP-lacking mice retained their body weight and fat mass at levels similar to those of their lean littermates, as previously reported in GIPRKO mice, in mice with K-cell ablation (19) and in mice with chemical inhibition of GIPR signaling (14).”
BackgroundResultSong, D. H., Getty–Kaushik, L., Tseng, E., Simon, J., Corkey, B. E., & Wolfe, M. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.005 · Cited by 137 · cited 1×
“GIP increases the adipose tissue volume directly (33,34) by binding to its receptors located on the adipocytes and indirectly by potentiating b-cell secretion of insulin, which is known to be involved in adipocyte fat deposition (35).”
Background
Cited by
Specialized metabolites from the microbiome in health and disease
Sharon, G., Garg, N., Debelius, J., Knight, R., Dorrestein, P. C., & Mazmanian, S. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.016 · Cited by 544
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Additional structural modifications included (i) substitution with aminoisobutyric acid at position 2 to increase resistance to DPP-4-mediated cleavage and inactivation, (ii) the addition of a Cterminal extension with 9 amino acids from exendin-4 to enhance structural stability, and (iii) acylation with a C16:0 fatty…”
BackgroundKillion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00966-w · Cited by 218
“Genome-wide association studies (GWAS) in humans show that the GIPR locus contributes to body weight (BW) regulation and GIPR knockout mice are protected from diet-induced obesity (DIO) 27–32 .”
Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02488-y · Cited by 200
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Prediction of Causal Candidate Genes in Coronary Artery Disease Loci
Brænne, I., Civelek, M., Vilne, B., Di Narzo, A., Johnson, A. D., Zhao, Y., Reiz, B., Codoni, V., Webb, T. R., Foroughi Asl, H., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306108 · Cited by 109
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106
Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65
GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells
Hansen, M. S., Søe, K., Christensen, L. L., Fernandez-Guerra, P., Hansen, N. W., Wyatt, R. A., Martin, C., Hardy, R. S., Andersen, T. L., Olesen, J. B., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac004 · Cited by 62
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus
Fu, Y., Kaneko, K., Lin, H.-Y., Mo, Q., Xu, Y., Suganami, T., Ravn, P., & Fukuda, M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa102 · Cited by 38
Boer, G. A., Keenan, S. N., Miotto, P. M., Holst, J. J., & Watt, M. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00646.2020 · Cited by 38
Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
Razny, U., Kiec-Wilk, B., Polus, A., Goralska, J., Malczewska-Malec, M., Wnek, D., Zdzienicka, A., Gruca, A., Childs, C. E., Kapusta, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.05.001 · Cited by 27
Wean, J., Kowalsky, A. H., Laker, R., Will, S., Drucker, D. J., Rhodes, C. J., & Seeley, R. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102074 · Cited by 28
Characterization of prevalent genetic variants in the Estonian Biobank body-mass index GWAS
Abner, E., Batool, K., Taba, N., Nikopensius, T., Läll, K., Alekseienko, A., Eriksson, A., Rämö, J., Haapaniemi, H., Kariis, H. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64006-9 · Cited by 2
Metadata
- Authors
- Nasteska, D., Harada, N., Suzuki, K., Yamane, S., Hamasaki, A., Joo, E., Iwasaki, K., Shibue, K., Harada, T., & Inagaki, N.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-06-14
- Volume
- 63
- Issue
- 7
- Pages
- 2332-2343
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2132198562
- Cited by
- 171
- References
- 11
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.